Stryker Corporation (SYK) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $310.18 (+0.75%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 4, 2026 | Matthew Taylor | Jefferies | $465.00 | +49.9% |
| Jan 30, 2026 | Mike Matson | Needham | $454.00 | +46.4% |
| Jan 30, 2026 | Ryan Zimmerman | BTIG | $412.00 | +32.8% |
| Jan 9, 2026 | Lee Hambright | Bernstein | $465.00 | +49.9% |
| Nov 14, 2025 | Richard Newitter | Truist Financial | $400.00 | +29.0% |
| Nov 14, 2025 | Shagun Singh | RBC Capital | $435.00 | +40.2% |
| Nov 14, 2025 | Mike Matson | Needham | $448.00 | +44.4% |
| May 5, 2025 | Lee Hambright | Bernstein | $450.00 | +45.1% |
| Apr 14, 2025 | Ryan Zimmerman | BTIG | $403.00 | +29.9% |
| Feb 3, 2025 | David Toung | Argus Research | $450.00 | +45.1% |
| Dec 18, 2024 | Richard Newitter | Truist Financial | $409.00 | +31.9% |
| Dec 2, 2024 | Patrick Wood | Morgan Stanley | $445.00 | +43.5% |
| Oct 31, 2024 | Joanne Wuensch | Citigroup | $411.00 | +32.5% |
| Oct 30, 2024 | Matt O'Brien | Piper Sandler | $420.00 | +35.4% |
| Oct 30, 2024 | Richard Newitter | Truist Financial | $380.00 | +22.5% |
| Oct 30, 2024 | Kyle Rose | Canaccord Genuity | $400.00 | +29.0% |
| Oct 30, 2024 | Ryan Zimmerman | BTIG | $394.00 | +27.0% |
| Oct 14, 2024 | Richard Newitter | Truist Financial | $370.00 | +19.3% |
| Sep 10, 2024 | Matt O\'Brien | Piper Sandler | $380.00 | +22.5% |
| Aug 28, 2024 | Ryan Zimmerman | BTIG | $374.00 | +20.6% |
Top Analysts Covering SYK
SYK vs Sector & Market
| Metric | SYK | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.29 | 2.24 | 2.40 |
| Analyst Count | 21 | 8 | 19 |
| Target Upside | +24.4% | +11475.0% | +17.1% |
| P/E Ratio | 35.90 | 3.88 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $26.94B | $27.33B | $27.56B | 21 |
| 2027-03-31 | $6.79B | $6.86B | $6.91B | 7 |
| 2027-06-30 | $7.04B | $7.11B | $7.16B | 7 |
| 2027-09-30 | $7.07B | $7.14B | $7.18B | 7 |
| 2027-12-31 | $8.38B | $8.47B | $8.52B | 7 |
| 2028-03-31 | $7.22B | $7.30B | $7.34B | 6 |
| 2028-06-30 | $7.38B | $7.45B | $7.50B | 6 |
| 2028-09-30 | $7.48B | $7.55B | $7.60B | 6 |
| 2028-12-31 | $8.87B | $8.96B | $9.01B | 6 |
| 2029-12-31 | $34.46B | $35.10B | $35.55B | 9 |
| 2030-12-31 | $37.17B | $37.85B | $38.34B | 13 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $14.05 | $15.00 | $15.11 | 16 |
| 2027-03-31 | $3.46 | $3.50 | $3.53 | 10 |
| 2027-06-30 | $3.87 | $3.93 | $3.96 | 7 |
| 2027-09-30 | $3.94 | $3.99 | $4.02 | 7 |
| 2027-12-31 | $5.33 | $5.40 | $5.44 | 14 |
| 2028-03-31 | $3.98 | $4.03 | $4.06 | 11 |
| 2028-06-30 | $4.26 | $4.32 | $4.35 | 8 |
| 2028-09-30 | $4.29 | $4.34 | $4.38 | 8 |
| 2028-12-31 | $5.87 | $5.95 | $6.00 | 15 |
| 2029-12-31 | $20.62 | $21.11 | $21.47 | 1 |
| 2030-12-31 | $22.54 | $23.08 | $23.47 | 1 |
Frequently Asked Questions
What is the analyst consensus for SYK?
The consensus among 21 analysts covering Stryker Corporation (SYK) is Buy with an average price target of $428.67.
What is the highest price target for SYK?
The highest price target for SYK is $465.00, set by Matthew Taylor at Jefferies on 2026-03-04.
What is the lowest price target for SYK?
The lowest price target for SYK is $260.00, set by Matt O’Brien at Piper Sandler on 2022-09-24.
How many analysts cover SYK?
21 analysts have issued ratings for Stryker Corporation in the past 12 months.
Is SYK a buy or sell right now?
Based on 21 analyst ratings, SYK has a consensus rating of Buy (2.29/5) with a +24.4% upside to the consensus target of $428.67.
What are the earnings estimates for SYK?
Analysts estimate SYK will report EPS of $15.00 for the period ending 2026-12-31, with revenue estimated at $27.33B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.